Project Grant 2507269
Award Date
4/15/25
Completion Date
3/31/26
Dollars Obligated
$305K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Boston, MA 02134, USA
Similar Awards
This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) Program (CFDA 47.084) Project Grant award of $275,000 provides funding to Illuminate Therapeutics, Inc. to develop their Light Activated Drug Delivery and Release (LADDR) platform technology. The objective is to improve patient outcomes in the treatment of head and neck and esophageal cancers, which represent a combined market of over $2.34B in 2021 growing at 10.5% annually. The key focus of this SBIR Phase...
This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $295,000 to Theracea Pharma LC focuses on the development of 18F-radiotracer kits for detecting biomarkers using positron emission tomography (PET). The project aims to create innovative diagnostic tools to enhance healthcare and patient outcomes by providing clinicians with precise and reliable information for disease management. It involves collaborations between industry and...
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Oncoblaze LLC to develop a novel medical device for targeted chemotherapy delivery to treat cancer tumor recurrence. The project aims to create a device prototype that uses an infrared laser to precisely heat and trigger the release of chemotherapy drugs in the tissue surrounding a surgically removed tumor. The device will also...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,990 aims to advance the regulatory pathway for commercializing space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The project, led by Eascra Biotech, Inc., a for-profit small business in Pawtucket, RI, focuses on demonstrating the comparability of space-manufactured JBNPs to earth-made counterparts. JBNPs offer...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
This award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $303,864 to Core Biotherapeutics Inc., a for-profit organization, to develop a platform for designing disruptive drug candidates that can address high unmet medical needs. The project aims to determine the biological laws governing molecular networks that drive diseases and program these into an efficient, scalable algorithm for drug target discovery. This...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...